NextPlat (NXPL) Net Income towards Common Stockholders (QoQ) (2010 - 2026)
Powered by 
Analysis
NextPlat (NXPL) Net Income towards Common Stockholders (QoQ) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.34 Bn | 38.68 Bn | 2.15 Bn |
| 2 | Viatris | 19.39 Bn | 18.50 Bn | 1.46 Bn |
| 3 | Dr Reddys Laboratories | 9.99 Bn | 9.85 Bn | 396.53 Mn |
| 4 | Amneal Pharmaceuticals | 5.57 Bn | 5.53 Bn | 334.51 Mn |
| 5 | Bausch Health Companies | 2.45 Bn | 1.58 Bn | 2.10 Bn |
| 6 | Ani Pharmaceuticals | 1.70 Bn | 1.34 Bn | 165.89 Mn |
| 7 | Alvotech | 1.66 Bn | 1.52 Bn | 2.56 Mn |
| 8 | Amphastar Pharmaceuticals | 985.90 Mn | 695.77 Mn | 93.47 Mn |
| 9 | Fennec Pharmaceuticals | 434.07 Mn | 392.82 Mn | 17.15 Mn |
| 10 | NextPlat | 24.77 Mn | 12.93 Mn | 4.69 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 87.12% |
| Mar 31, 2026 | 82.52% |
| Dec 31, 2025 | -192.68% |
| Sep 30, 2025 | -22.14% |
| Jun 30, 2025 | 7.88% |
| Mar 31, 2025 | 19.69% |
| Dec 31, 2024 | 42.65% |
| Sep 30, 2024 | 20.62% |
| Jun 30, 2024 | -258.61% |
| Mar 31, 2024 | 12.78% |
| Dec 31, 2023 | -149.25% |
| Sep 30, 2023 | 179.43% |
| Jun 30, 2023 | -265.71% |
| Mar 31, 2023 | -26.04% |
| Dec 31, 2022 | 83.52% |
| Sep 30, 2022 | -245.03% |
| Jun 30, 2022 | -94.79% |
| Mar 31, 2022 | 75.99% |
| Dec 31, 2021 | -53.57% |
| Sep 30, 2021 | -58.09% |